Last reviewed · How we verify
NCT04912024: COMPARE
Comparative Outcome Measures of Patients Receiving Acute Renal ThErapy Study
trial testing Intermittent Renal Replacement Therapy using the Tablo Hemodialysis System in End Stage Kidney Disease in 458 participants. Completed in 15 June 2022.
15 June 2022
Quick facts
| Lead sponsor | Outset Medical |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 458 |
| Start date | 15 May 2021 |
| Primary completion | 15 June 2022 |
| Estimated completion | 15 June 2022 |
| Sites | 2 locations across United States |
Drugs / interventions tested
- Intermittent Renal Replacement Therapy using the Tablo Hemodialysis System
- Intermittent Renal Replacement Therapy using Conventional Hemodialysis Systems
Conditions studied
- End Stage Kidney Disease — all drugs for End Stage Kidney Disease →
- End Stage Renal Disease — all drugs for End Stage Renal Disease →
- Acute Kidney Injury — all drugs for Acute Kidney Injury →
Sponsor
Outset Medical — full company profile →
Who can join
18 and older, any sex, with End Stage Kidney Disease or End Stage Renal Disease. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Retrospective, multicenter, comparative, post-market study of the Tablo Hemodialysis System in hospitalized participants with End-Stage Renal Disease or Acute Kidney Injury.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Utility of a water-sparing approach for reducing dialysate flow rates in hospitalized patients with kidney failure.
Parikh A, Drake K, Woda C, D'Alessandri-Silva C, et al · · 2025 · PMID 40321105 · DOI 10.1177/03913988251337228
Verify or expand the search:
- PubMed search for NCT04912024
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for End Stage Kidney Disease
Currently open trials in the same condition.
- NCT06356168 — Virtual Reality in End Stage Kidney Disease · NA · recruiting
- NCT05715814 — meChANisms and sAfety of SGLT2 Inhibition in peRitoneal dialYsis · Phase 3 · recruiting
- NCT05642364 — Virtual Reality in Hemodialysis to Improve Psychological Well-being · NA · active not recruiting
- NCT05642156 — Hemodynamics in Chronic Hemodialysis Patients Undergoing Isolated Ultrafiltration Compared to Conventional Hemodialysis · NA · recruiting
- NCT05311956 — Pain Reduction Using NEurostimulation Study · NA · active not recruiting
Other Outset Medical trials
Trials by the same sponsor.
- NCT04912050 — EXtension of Tablo TrEatmeNt Duration Registry · completed
- NCT04526301 — Home With TablO outcoMEs (HOME) Registry · unknown
- NCT05947708 — The Study of Intradialytic Symptoms in Subjects Treated With Qd 500vs Qd 300 · NA · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04912024 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Outset Medical
- Last refreshed: 12 August 2022
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04912024.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing